利用透析机构实践差异理解公共政策效果:来自透析结局与实践模式研究(DOPPS)的洞见
该研究利用透析机构比较星级评分系统(DFC SRS)和DOPPS数据,分析透析机构在死亡率、住院率、输血率等临床指标上的实践差异。机构间差异通常大于纵向趋势,部分指标分布过窄可能价值存疑,而甲状旁腺激素、铁蛋白和治疗时间等领域未受现有政策覆盖,需创新综合护理模式。
要点
- 机构间死亡率、住院率和输血率的标准化比率10th/90th百分位差异近两倍至近四倍。
- DFC SRS评定的瘘管使用率和导管使用>90天比例机构间差异显著。
- Kt/V>1.2和血清钙>10.2 mg/dl的机构分布较窄,可能价值存疑。
核心结论
- 机构间实践差异通常大于 prevailing 纵向趋势,不应被忽视。
- 结合全国代表性观察数据库(如DOPPS)与ESRD登记系统可为政策制定者提供评估机构差异、制定政策和监测非预期效应的额外工具。
研究设计与样本
- 基于DFC SRS和DOPPS的观察性分析,使用Medicare索赔数据(2014年7月)和DOPPS数据评估透析机构实践差异。
- 研究对象为接受血液透析的患者,具体样本量原文未报告。
主要发现
- DFC SRS中,死亡率标准化死亡比10th/90th百分位为0.71和1.34,住院率标准化住院比10th/90th百分位为0.64和1.37,输血率标准化输血比10th/90th百分位为0.43和1.65。
- Medicare索赔数据显示,6个月内住院患者比例10th/90th百分位为27%和50%,输血患者比例10th/90th百分位为3%和17%。
- DFC SRS评定的瘘管使用率10th/90th百分位为50%和78%,导管使用>90天比例10th/90th百分位为3%和19%。
- DFC SRS评定的成人血液透析Kt/V>1.2比例10th/90th百分位为84%和97%,总血清钙>10.2 mg/dl的机构中位数1%,75th/90th百分位为3%和5%。
- DOPPS中机构中位血清甲状旁腺激素10th/90th百分位为290 pg/ml和629 pg/ml,铁蛋白10th/90th百分位为469 ng/ml和1143 ng/ml,机构平均治疗时间10th/90th百分位为204分钟和234分钟,相差30分钟。
临床怎么用
- 作者认为,血清甲状旁腺激素和铁蛋白水平上升及治疗时间普遍偏短是现有政策未覆盖的领域,可能反映政策或报销压力的非预期后果,值得关注。
- 作者认为,需要创新综合护理模式覆盖晚期CKD和早期透析阶段,并更便于政策监管。
- 作者认为,结合全国代表性观察数据库和ESRD登记系统可帮助政策制定者评估机构差异、制定政策和监测非预期效应。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Recent Centers for Medicare & Medicaid Services policies have used dialysis facility practice variation to develop public ratings and adjust payments. In the Dialysis Facility Compare star rating system (DFC SRS), facility-relative rates of performance-based clinical measures varied nearly two-fold for mortality (standardized mortality ratio; 10th/90th percentiles: 0.71, 1.34) and hospitalization (standardized hospitalization ratio; 10th/90th percentiles: 0.64, 1.37), and nearly four-fold for transfusion (standardized transfusion ratio; 10th/90th percentiles: 0.43, 1.65). Medicare claims data (from July of 2014) demonstrate that facility variation for the proportions of patients on hemodialysis hospitalized (10th/90th percentiles: 27%, 50%) and transfused (10th/90th percentiles: 3%, 17%) within 6 months that far exceeds relatively modest recent overall longitudinal trends. DFC SRS-rated facility variation is also substantial for fistula (10th/90th percentiles: 50%, 78%) and catheter use >90 days (10th/90th percentiles: 3%, 19%). By contrast, DFC SRS-rated facility distributions for adult hemodialysis Kt/V>1.2 (10th/90th percentiles: 84%, 97%) and total serum calcium >10.2 mg/dl (median, 1%; 75th/90th percentiles: 3%, 5%) are quite narrow and may be of questionable value. Likewise, variation in the US Dialysis Outcomes and Practice Patterns Study is over two-fold for facility median serum parathyroid hormone (10th/90th percentiles: 290 pg/ml, 629 pg/ml) and ferritin (10th/90th percentiles: 469 ng/ml, 1143 ng/ml) levels, and facility mean treatment time varies by 30 minutes (10th/90th percentiles: 204 minutes, 234 minutes). Rising serum parathyroid hormone and ferritin levels, and generally short dialysis treatment time, represent areas unchecked by existing policy; both overall trends and facility variation in these values may reflect unintended consequences of policy or reimbursement pressures and therefore raise concern. Additionally, outcomes in the transition period from advanced CKD to dialysis remain poor, and policy initiatives and performance accountability in this area remain insufficient. Innovative models of comprehensive care in advanced CKD and the early dialysis period which are more amenable to policy oversight are needed. In summary, facility variation is typically larger than prevailing longitudinal trends, and should not be overlooked. The combination of nationally representative observational databases (e.g., the Dialysis Outcomes and Practice Patterns Study) and ESRD registries can provide policy makers with additional tools to evaluate facility variation, develop policies, and monitor unintended effects.
引用
- Fuller DS, Robinson BM. Facility Practice Variation to Help Understand the Effects of Public Policy: Insights from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Clin J Am Soc Nephrol. 2016. PMID: 28062678. doi:10.2215/CJN.03930416
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。